Not Approved, Not Listed: The HHS Peptide Proposal
The HHS is moving forward with an enforcement-discretion policy that creates a path for manufacturing and sale of some peptides, while side-stepping FDA's usual requirements.
Snake Oil to Compounded Peptides: Why We Ask For Evidence
The USA's path to legalizing peptides risks leaving consumers with unanswered questions about quality, safety and effectiveness.
Transdermal Vitamin and Wellness Patches: Hype versus Evidence
Wellness patches lack plausibility and evidence to demonstrate effectiveness
Generic GLP-1s are here (for some)
Will approved generic versions of Ozempic eliminate the grey market for compounding?
New Cautions About Vitamin B6 and Peripheral Neuropathy
Two countries are putting warnings and limits on Vitamin B6 supplements.
The FDA vs. Compounding Pharmacies: GLP-1 Edition
The FDA is determined to stop the sale of compounded GLP-1 drugs
Science vs. Hype: The Unproven Promise of NAD+ IV Therapy
Two new papers and renewed safety concerns for this popular (yet unproven) therapy.
Is the Homeopathic Industry “On the Ropes”?
The U.S. homeopathic industry is under growing regulatory and legal pressure.
99 Ways to Die – And How to Avoid them
An entertaining guide to death, with tips on how to avoid it, from an emergency medicine doctor.
Revolutions in Drug Delivery
New medicines are getting better. But so is our ability to get them where they need to go.

